Cordyceps: Exercise, Lung and Kidney Research

What is cordyceps?

“Cordyceps” covers several fungal ingredients. The traditional wild material is Ophiocordyceps sinensis. Modern supplements include cultured preparations such as Cs-4 and products made from another species, Cordyceps militaris. They are not the same ingredient. Some exercise studies also use multi-mushroom blends rather than cordyceps alone.

Traditional use and today’s preparations

The wild material behind the cordyceps tradition is a fungus–caterpillar complex found in cold climates. Memorial Sloan Kettering^[1] describes traditional Chinese uses for fatigue, cough and sexual dysfunction.

Cultivation has made several different ingredients available for study. Cs-4 is a named cultured preparation. Bailing is a preparation made from fermented mycelium—the growing fungal threads—identified as Hirsutella sinensis Cs-C-Q80. Cordyceps militaris is another species. These differences matter because the exercise, bronchitis and immune studies below did not test a single interchangeable product.

What people take cordyceps for

For someone considering it for fatigue, a performance-supplement trial does not establish treatment of persistent unexplained tiredness. That symptom deserves its own assessment.

What should you check on the label?

Look for the species or named cultured preparation, fruiting body versus mycelium, amount per serving, and whether it is a powder or extract. Fruiting body means the visible reproductive structure, and mycelium means the growing fungal threads. Neither is automatically the better clinical choice. The Cs-4 research concerns that named cultured preparation. A different militaris extract can have a different composition.

There is no official nutritional daily target for cordyceps.

For blends, require individual amounts. A total of 4 g shared across several mushrooms is not 4 g of cordyceps. A stated cordycepin amount measures one fungal compound.

What are the drawbacks and safety limitations?

The indexed NIH LiverTox summary^[2] reports no established association with liver injury.

The MSK interaction guidance^[1] does not quantify the additional bleeding or low-blood-sugar risk in people. It also advises avoidance in myelogenous cancers, which involve the bone marrow’s blood-forming cells, based on animal findings affecting immature blood cells.

Why do the exercise studies differ?

The 2010 Cs-4 pilot^[3] enrolled twenty adults aged 50–75; fifteen completed it. Some exercise thresholds improved within the active group: the points during increasing exertion when lactate accumulation or the associated breathing response becomes more prominent. A higher threshold could mean sustaining more work before that transition, but it is not itself a faster race result. Maximum oxygen uptake did not improve, and the overall comparison between the two groups was not significant.

The 2004 cyclist study^[4] tested 22 trained men and found no improvement in aerobic capacity or time-trial performance. Age, training status, duration and outcome all differed. A favorable change from baseline in a small group is also not automatically a demonstrated advantage over placebo.

A militaris-containing blend study^[5] tested 4 g/day of PeakO2, a six-mushroom mixture. Twenty-eight people completed the one-week comparison, which showed no significant advantage across the exercise outcomes. Ten volunteers continued to three weeks: six on the blend and four on placebo. That small extension found an advantage in maximum oxygen uptake, while the between-group threshold and endurance comparisons remained negative. The product’s sponsor helped fund the work.

A 2026 crossover trial^[6] tested a single 1 g dose of a standardized militaris extract in twelve young men. Reaction time after cycling favored the extract, but peak exercise oxygen uptake did not. Resting oxygen use increased; that measurement is not an endurance result.

A 2025 review of mushroom supplements in athletes^[7] reports favorable pooled cordyceps findings. Its small trials and differing preparations need to be read alongside the negative cyclist result. Pooling does not make Cs-4, a named extract and a multi-mushroom blend equivalent.

Amounts and duration in the studies

The older-adult trial's methods specify three 333 mg capsules, three times daily: approximately 3 g of Cs-4 a day, for twelve weeks. The abstract's compressed dose wording can be misread as one-third of that amount. The cyclist trial also used 3 g/day, but for five weeks and without benefit.

Chronic bronchitis: fewer flare-ups, unchanged lung function

A 2024 multicenter trial^[8] randomized 240 adults with recurrent chronic bronchitis; 238 took study treatment. They received Bailing Cs-C-Q80 at 2 g three times daily or placebo for 48 weeks, with usual rescue treatments allowed. Participants had relatively preserved measured lung function, so the results do not directly describe severe obstructive lung disease.

The average number of flare-ups was 0.43 with Bailing versus 1.56 with placebo during treatment. Lung-function tests and the timing and duration of attacks did not significantly improve. Overall symptom scores favored Bailing, but cough severity during acute attacks was worse. This distinction matters: fewer attacks and milder attacks are different outcomes.

Follow-up after treatment also favored Bailing for flare-up counts, although pandemic precautions complicated interpretation. The trial was hospital-funded. It offers a preparation-specific clinical signal, with contradictory symptom findings, rather than evidence that any cordyceps powder improves breathing.

In the 48-week bronchitis trial, adverse events were reported in 47 of 159 treated participants and 24 of 79 controls. Each group had six serious events affecting five patients. Similar proportions of affected participants in that study provide information about its Bailing preparation and selected patients, without establishing safety for other products. ^[8]

Kidney research concerns several different medical situations

Cordyceps has been studied alongside conventional kidney care. A 2014 Cochrane review^[9] included 22 studies and 1,746 participants. Some kidney laboratory measures favored supplementation, but the reviewers considered the evidence too weak for a definitive conclusion.

For people already on dialysis, a separate review^[10] included twelve studies and 655 participants. Some inflammation, nutrition and anemia measures improved, but creatinine did not. Adverse events were often poorly recorded, and the reviewers found insufficient evidence to recommend cordyceps as an added treatment.

Kidney transplantation poses another question because treatment must prevent rejection. A Cochrane transplant review^[11] assessed five studies involving 447 people. Comparisons included cordyceps versus azathioprine and cordyceps with lower-dose cyclosporine versus standard-dose cyclosporine. Some findings favored cordyceps, but there was no demonstrated survival advantage and study methods were poorly reported. These supervised regimens do not support changing anti-rejection medicines on one’s own.

A small blood-vessel imaging trial^[12] studied cordyceps around the use of contrast dye in 120 people with diabetes and reduced kidney function. Its abstract reports fewer kidney-injury events with treatment, but does not give the event counts for each arm. This is a preliminary finding in a specific procedure, not a general kidney-protection regimen.

A fermentation drink for primary insomnia

A 2025 placebo-controlled trial^[13] randomized 90 adults with primary insomnia—persistent sleep difficulty not attributed to another condition; 88 completed the analysis, 44 per group. Participants drank 150 mL of a cordyceps fermentation beverage or matching placebo six days a week for four weeks. Both groups used the same app and phone support.

On the Pittsburgh Sleep Quality Index, where lower scores mean fewer sleep problems, scores fell by 6.45 points with the beverage and 1.00 with placebo. Some early individual sleep measures did not meet the trial’s stricter statistical threshold. The study relied on questionnaires; it did not establish changes in objectively measured sleep stages or lasting benefit after treatment.

Three minor events involving increased defecation were reported in the active group and resolved within one to three days. The manufacturer supplied both drinks, and the exact preparation matters: this result does not establish an equivalent capsule dose. People with psychiatric conditions or insomnia caused by another condition were excluded.

Long COVID and immune studies

A randomized Cs4 trial^[14] assigned 110 people with long COVID to twelve weeks of supplementation or a waiting list. The supplemented group improved more on a symptom questionnaire, with favorable fatigue, insomnia and respiratory-symptom results. Because the control group waited without placebo, expectations and knowing the treatment assignment could affect these self-reported outcomes. The study provides a lead for better-controlled trials, rather than a dependable treatment recommendation.

Immune research also includes a 2024 fermented militaris beverage trial^[15] in forty healthy adults. The daily 75 mL drink supplied at least 2.85 mg of cordycepin and was compared with the same fruit-juice base. Selected measures of natural-killer-cell activity improved, particularly in women at eight weeks; antibody levels and several immune-cell counts did not differ. With ten people of each sex per treatment group, the subgroup findings are small. The experiment measured immune activity, not whether people caught fewer infections.

Bottom line

Cordyceps is a family of different preparations with different research results. Cs-4 has mixed exercise findings, including a negative trained-cyclist trial. The Bailing bronchitis study found fewer flare-ups but unchanged lung function and worse cough during attacks. One fermentation drink improved sleep questionnaires over four weeks in primary insomnia. Kidney and long-COVID studies add clinical questions whose answers remain uncertain.

A cordycepin number, a traditional reputation or an immune-cell result cannot by itself tell you whether a retail product will improve performance or symptoms.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly